Olema Pharmaceuticals Inc

NASDAQ:OLMA   3:59:50 PM EDT
4.18
+0.11 (+2.70%)
Products, Strategic Combinations

Olema Oncology, Aurigene Announce Exclusive Collaboration, License Agreement To Discover And Develop Novel Cancer Therapies

Published: 06/09/2022 12:13 GMT
Olema Pharmaceuticals Inc (OLMA) - Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies.
Olema Pharmaceuticals Inc - Olema Will Make an Upfront Licensing Payment of $8 Million for Rights to a Pre-existing Aurigene Program.
Olema Pharmaceuticals Inc - Aurigene Will Be Eligible for Up to $60 Million in Potential Clinical Development and Regulatory Milestones.
Olema Pharmaceuticals Inc - Aurigene Will Be Eligible for Up to $370 Million in Potential Commercial Milestones.
Olema Pharmaceuticals Inc - Aurigene Will Be Eligible for Royalties Ranging From Mid-single Digits to Low Double Digits Based on Annual Net Sales.
Olema Pharmaceuticals Inc - During Research Term, Olema Will Contribute Funding to Aurigene to Facilitate Ongoing Discovery Efforts.
Olema Pharmaceuticals Inc - Continues to Be Well Capitalized With Sufficient Cash to Fund Planned Research and Development Operations Into Second Half of 2024.